PT-141 (Bremelanotide) vs MOTS-c: Cost and Access Head-to-Head

Why These Two Peptides Get Compared

PT-141 and MOTS-c both fall under the broad "peptide therapy" umbrella, and clinics offering regenerative or optimization medicine frequently stock both. That shared shelf space drives patient confusion. The two peptides share almost nothing else. PT-141 (bremelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone that acts on melanocortin receptors in the central nervous system to increase sexual desire. MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that was first characterized in 2015 by Lee et al. as an exercise mimetic and insulin sensitizer in murine models.

The comparison matters most at the pharmacy counter. One peptide carries full FDA backing with a defined reimbursement path. The other exists in a regulatory gray zone where product quality, dosing standards, and payer coverage are all uncertain. Patients weighing peptide options deserve a clear picture of what each one costs, how to get it, and what clinical evidence supports the price tag.

FDA Approval and Regulatory Status

PT-141 received FDA approval on June 21, 2019, under the brand name Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women. The approval rested on two Phase III RECONNECT trials enrolling over 1,200 women total, which demonstrated statistically significant increases in desire and reductions in distress compared to placebo over 24 weeks. The FDA granted it a specific NDA (210557), and AMAG Pharmaceuticals (now Covis Pharma) markets the autoinjector.

MOTS-c has no FDA approval, no active NDA, and no breakthrough therapy designation. It is not listed in the FDA's Orange Book. The peptide is classified as a research compound by most suppliers. Some compounding pharmacies prepare it under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, though the FDA has not formally added MOTS-c to the bulk drug substance list for compounding. This distinction matters: a peptide without explicit compounding authorization may face enforcement action at any time.

The regulatory gap between these two peptides is not a technicality. It determines insurance eligibility, prescriber liability, and whether the product you inject has undergone third-party purity testing under cGMP conditions.

Mechanism of Action: Different Targets, Different Biology

PT-141 works in the brain. After subcutaneous injection, bremelanotide crosses into the central nervous system and binds melanocortin-4 receptors (MC4R) in the hypothalamus. This activation modulates dopaminergic and oxytocinergic pathways involved in sexual arousal. The RECONNECT trial data showed that 1.75 mg administered at least 45 minutes before anticipated sexual activity produced a mean increase of 0.35 points on the Female Sexual Distress Scale (revised) compared to placebo (P<0.05). The effect is acute, not cumulative, and the drug is dosed on demand rather than daily.

MOTS-c works in peripheral tissues. The peptide activates AMP-activated protein kinase (AMPK) and regulates the folate cycle and de novo purine biosynthesis. In the foundational 2015 study by Lee et al., MOTS-c administration in mice prevented age-dependent and high-fat-diet-induced insulin resistance, reduced body weight gain, and improved glucose disposal. Circulating MOTS-c levels in humans decline with age and correlate inversely with insulin resistance markers. A small 2021 human study (N=10) showed that MOTS-c injection improved glucose regulation in obese participants, but the sample size precludes any definitive clinical conclusions.

These mechanisms do not overlap. A patient using PT-141 for sexual desire will not see metabolic benefits. A patient using MOTS-c for insulin sensitivity will not experience changes in libido.

Cost Breakdown: What You Will Actually Pay

PT-141 (Vyleesi) Brand Pricing

The branded Vyleesi autoinjector carries a wholesale acquisition cost (WAC) of approximately $950 for a pack of four 1.75 mg doses. At the recommended maximum of eight doses per month, a patient using the brand product could spend $1,900 per month at list price. Most patients use four to six doses monthly, placing realistic out-of-pocket costs between $850 and $1,400 without insurance.

Manufacturer copay cards can reduce the cost to $50 per fill for commercially insured patients. Covis Pharma's patient assistance program may cover part of the cost for uninsured patients meeting income criteria.

PT-141 Compounded Pricing

Compounded bremelanotide from a 503B outsourcing facility typically runs $150 to $350 per month for comparable dosing. Compounded versions come as multi-dose vials requiring the patient to draw and measure each injection. The tradeoff is clear: lower cost, more preparation, and variable quality depending on the pharmacy.

MOTS-c Pricing

MOTS-c pricing is harder to pin down because there is no standardized commercial product. Compounding pharmacies charge between $150 and $400 per month for a typical dosing protocol of 5 mg to 10 mg injected two to three times per week. Research-grade MOTS-c from peptide suppliers may cost less ($80 to $200 per 10 mg vial) but is labeled "for research use only" and carries no guarantee of pharmaceutical-grade purity.

Without FDA approval, there is no WAC, no manufacturer copay card, and no patient assistance program for MOTS-c. Every dollar comes directly from the patient.

Side-by-Side Cost Table

| Factor | PT-141 (Vyleesi) | PT-141 (Compounded) | MOTS-c | |---|---|---|---| | Monthly cost (no insurance) | $850 to $1,400 | $150 to $350 | $150 to $400 | | Insurance eligible | Yes (with PA) | Rarely | No | | Copay card available | Yes | No | No | | Patient assistance | Yes | No | No | | cGMP manufactured | Yes | Varies by pharmacy | Rarely verified |

Insurance Coverage and Prior Authorization

PT-141 is listed on some commercial formularies, typically as a non-preferred specialty drug on Tier 4 or Tier 5. Most insurers require prior authorization with documentation of an HSDD diagnosis, failure of non-pharmacologic interventions, and confirmation that the patient is premenopausal. According to Endocrine Society clinical practice guidelines, pharmacologic treatment for sexual dysfunction should follow a thorough psychosocial and medical evaluation.

Coverage varies significantly by plan. UnitedHealthcare and Aetna have published coverage criteria for Vyleesi. Cigna and Anthem list it as a medical exception in some markets. Medicare Part D does not cover Vyleesi because HSDD treatment is excluded from the Part D statutory category.

MOTS-c has no insurance coverage pathway. No CPT code, no HCPCS code, and no prior authorization form exists for this peptide. Patients paying for MOTS-c cannot submit claims to any known U.S. payer. Some patients use health savings accounts (HSA) or flexible spending accounts (FSA) to cover the cost, but reimbursement depends on whether their plan administrator considers it a qualified medical expense. Without an FDA-approved indication, many administrators reject the claim.

Clinical Evidence: Depth and Quality

The evidence base for PT-141 is orders of magnitude deeper than for MOTS-c. The RECONNECT program included two randomized, double-blind, placebo-controlled Phase III trials (Study 301 and Study 302) with a combined enrollment of 1,247 premenopausal women with HSDD. Study 301 demonstrated that bremelanotide 1.75 mg produced a statistically significant improvement in the coprimary endpoints: an increase of 0.35 on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 and an increase of 1.2 satisfying sexual events per month compared to placebo.

MOTS-c human data is sparse. The 2015 Lee et al. paper that put MOTS-c on the map was conducted entirely in C57BL/6 mice. A 2021 pilot study published in the Journal of Clinical Endocrinology & Metabolism examined MOTS-c in 10 obese men and showed improved glucose metabolism after a single infusion, but the study had no placebo arm and lasted only days. No Phase II or Phase III trial for MOTS-c has been registered on ClinicalTrials.gov as of May 2026.

"The clinical data supporting MOTS-c in humans is still very early-stage. We have promising mechanistic work and animal data, but we are years away from the kind of evidence that would support an FDA filing," noted Dr. Pinchas Cohen, Dean of the USC Leonard Davis School of Gerontology and senior author on the original MOTS-c discovery.

Safety Profiles

PT-141's safety data comes from over 3,600 patients across clinical development. The most common adverse effects are nausea (reported in 40% of patients in the RECONNECT trials), flushing (20%), and headache (13%). Nausea is typically transient, peaking within two hours of injection and resolving within four hours. The FDA label includes a warning about transient blood pressure increases (mean systolic rise of 2 to 3 mmHg) and focal hyperpigmentation with repeated use. PT-141 is limited to eight doses per month based on cardiovascular safety data.

MOTS-c safety data in humans is minimal. The 10-subject pilot study reported no serious adverse events, but a sample of 10 people over a short duration cannot characterize a safety profile. Animal studies show no obvious toxicity signals at therapeutic doses. The real safety concern with MOTS-c is product quality: without cGMP manufacturing requirements, contaminants, endotoxins, or degraded peptide fragments could enter the vial. A 2023 analysis of peptides purchased from online research suppliers found that only 62% matched their labeled identity and purity.

"When a patient buys a research peptide online, they are trusting a supply chain with no regulatory oversight. The peptide might be pure. It might contain bacterial endotoxins. There is no way to know without independent testing," observed Dr. Thomas O'Connell, a board-certified endocrinologist and member of the American Association of Clinical Endocrinology.

Prescriber and Access Pathways

Getting PT-141 requires a licensed prescriber (MD, DO, NP, or PA in most states) to write a prescription after diagnosing HSDD using validated screening tools like the Decreased Sexual Desire Screener. The prescription goes to a specialty pharmacy or, for compounded versions, a 503A or 503B compounding pharmacy. Telehealth platforms, including HealthRX, can prescribe PT-141 after a clinical evaluation.

Getting MOTS-c is less straightforward. Because MOTS-c is not FDA-approved, prescribers who order it assume liability for an off-label, unapproved product. Some anti-aging and functional medicine clinics prescribe MOTS-c through compounding pharmacies, often alongside other peptides like BPC-157 or CJC-1295. Patients can also purchase MOTS-c directly from research chemical suppliers without a prescription, though doing so means injecting a product with no physician oversight and no quality assurance.

State pharmacy boards have varying positions on compounding unapproved peptides. In 2023, the FDA issued warning letters to several compounding pharmacies for marketing unapproved peptide products with therapeutic claims. While these letters did not name MOTS-c specifically, the regulatory direction is clear: the FDA is tightening oversight of the compounded peptide market.

Who Should Consider Each Peptide

PT-141 is appropriate for premenopausal women diagnosed with acquired, generalized HSDD who have not responded adequately to psychosocial interventions. It is also used off-label in some male sexual dysfunction protocols, though this application lacks Phase III data. Patients who can tolerate nausea and who prefer on-demand dosing over daily medication (such as flibanserin) are good candidates.

MOTS-c may interest patients seeking metabolic optimization who have exhausted or are not candidates for FDA-approved therapies like metformin or GLP-1 receptor agonists. The peptide's theoretical appeal lies in its AMPK activation and exercise-mimetic properties. Any patient considering MOTS-c should understand that they are using a compound with preclinical evidence, no standardized dosing, and no regulatory safety net. A prescriber experienced with peptide therapies and a pharmacy that provides certificates of analysis are non-negotiable requirements.

Switching Between PT-141 and MOTS-c

Switching from one to the other implies interchangeability. These peptides are not interchangeable. They treat different conditions through different mechanisms. A patient dissatisfied with PT-141 for sexual desire should explore flibanserin, testosterone therapy (where appropriate), or psychosexual counseling rather than a metabolic peptide.

A patient dissatisfied with MOTS-c for metabolic goals should consider GLP-1 receptor agonists, SGLT2 inhibitors, or structured exercise programs with documented insulin-sensitizing effects. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo, a magnitude of effect that no peptide without Phase III data can match.

The only scenario where a patient might use both is in a polypharmacy protocol addressing sexual dysfunction and metabolic health simultaneously. Even then, the peptides would be prescribed for independent indications, not as alternatives to each other.